Dahut WL - Search Results

1

DPYD Testing: Time to Put Patient Safety First.

Baker SD, Bates SE, Brooks GA, Dahut WL, Diasio RB, El-Deiry WS, Evans WE, Figg WD, Hertz DL, Hicks JK, Kamath S, Kasi PM, Knepper TC, McLeod HL, O'Donnell PH, Relling MV, Rudek MA, Sissung TM, Smith DM, Sparreboom A, Swain SM, Walko CM. Baker SD, et al. Among authors: dahut wl. J Clin Oncol. 2023 May 20;41(15):2701-2705. doi: 10.1200/JCO.22.02364. Epub 2023 Feb 23. J Clin Oncol. 2023. PMID: 36821823 Free PMC article. No abstract available.

2

Taxanes in hormone-refractory prostate cancer.

Kang MH, Figg WD, Dahut W. Kang MH, et al. Cancer Pract. 1999 Sep-Oct;7(5):270-2. doi: 10.1046/j.1523-5394.1999.75005.x. Cancer Pract. 1999. PMID: 10687598 Review. No abstract available.

3

Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.

Rudek MA, Figg WD, Dyer V, Dahut W, Turner ML, Steinberg SM, Liewehr DJ, Kohler DR, Pluda JM, Reed E. Rudek MA, et al. J Clin Oncol. 2001 Jan 15;19(2):584-92. doi: 10.1200/JCO.2001.19.2.584. J Clin Oncol. 2001. PMID: 11208854 Clinical Trial.

4

Reversible sideroblastic anemia associated with the tetracycline analogue COL-3.

Rudek MA, Horne M, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E. Rudek MA, et al. Am J Hematol. 2001 May;67(1):51-3. doi: 10.1002/ajh.1076. Am J Hematol. 2001. PMID: 11279658 Free article.

5

Drug-induced lupus associated with COL-3: report of 3 cases.

Ghate JV, Turner ML, Rudek MA, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E. Ghate JV, et al. Arch Dermatol. 2001 Apr;137(4):471-4. Arch Dermatol. 2001. PMID: 11295928 Clinical Trial.

6

Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning.

Carrasquillo JA, Whatley M, Dyer V, Figg WD, Dahut W. Carrasquillo JA, et al. J Nucl Med. 2001 Sep;42(9):1359-63. J Nucl Med. 2001. PMID: 11535725 Free article.

7

Suramin's development: what did we learn?

Kaur M, Reed E, Sartor O, Dahut W, Figg WD. Kaur M, et al. Invest New Drugs. 2002 May;20(2):209-19. doi: 10.1023/a:1015666024386. Invest New Drugs. 2002. PMID: 12099581 Review.

8

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, Kang MH, Figg WD, Wainer I, Chaissang C, Li MZ, Hawkins MJ. Marshall JL, et al. J Exp Ther Oncol. 2002 Nov-Dec;2(6):325-32. doi: 10.1046/j.1359-4117.2002.01039.x. J Exp Ther Oncol. 2002. PMID: 12440223 Clinical Trial.

9

Malignant ascites as only manifestation of metastatic prostate cancer.

Saif MW, Figg WD, Hewitt S, Brosky K, Reed E, Dahut W. Saif MW, et al. Prostate Cancer Prostatic Dis. 1999 Dec;2(5/6):290-293. doi: 10.1038/sj.pcan.4500385. Prostate Cancer Prostatic Dis. 1999. PMID: 12497177

10

Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide.

Ando Y, Price DK, Dahut WL, Cox MC, Reed E, Figg WD. Ando Y, et al. Among authors: dahut wl. Cancer Biol Ther. 2002 Nov-Dec;1(6):669-73. doi: 10.4161/cbt.318. Cancer Biol Ther. 2002. PMID: 12642692 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

219 results

Search Page